Concerta Extended Release Tablets Nowa Zelandia - angielski - Medsafe (Medicines Safety Authority)

concerta extended release tablets

janssen-cilag (new zealand) ltd - methylphenidate hydrochloride 18mg (drug layer 1, drug layer 2 & drug coat) - modified release tablet - 18 mg - active: methylphenidate hydrochloride 18mg (drug layer 1, drug layer 2 & drug coat) excipient: butylated hydroxytoluene carnauba wax cellulose acetate hypromellose ferric oxide, green (push layer) iron oxide yellow opacode black ns-78-17715 opadry clear ys-1-19025-a opadry yellow ys-30-12788a phosphoric acid poloxamer 188 polyethylene oxide povidone sodium chloride stearic acid succinic acid - concerta is indicated for the treatment of attention deficit hyperactivity disorder (adhd). a diagnosis of attention deficit hyperactivity disorder (adhd; dsm-iv) implies the presence of hyperactive-impulsive or inattentive symptoms that caused impairment and were present before age 7 years. need for comprehensive treatment programme: concerta is indicated as an integral part of a total treatment program for adhd that may include other measures (psychological, educational and social) for patients with this syndrome. stimulants are not intended for use in the patient who exhibits symptoms secondary to environmental factors and/or other primary psychiatric disorders, including psychosis. appropriate educational placement is essential and psychosocial intervention is often helpful. when remedial measures alone are insufficient, the decision to prescribe stimulant medication will depend upon the physician's assessment of the chronicity and severity of the patient's symptoms. long term use: the effectiveness of concerta for long-term use has not been systematically evaluated in controlled trials. therefore the physician who elects to use concerta for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient.

Concerta Extended Release Tablets Nowa Zelandia - angielski - Medsafe (Medicines Safety Authority)

concerta extended release tablets

janssen-cilag (new zealand) ltd - methylphenidate hydrochloride 36mg (drug layer 1, drug layer 2 & drug coat) - modified release tablet - 36 mg - active: methylphenidate hydrochloride 36mg (drug layer 1, drug layer 2 & drug coat) excipient: butylated hydroxytoluene carnauba wax cellulose acetate hypromellose ferric oxide, green (push layer) iron oxide yellow opacode black ns-78-17715 opadry clear ys-1-19025-a opadry white y-30-18037 phosphoric acid poloxamer 188 polyethylene oxide povidone sodium chloride stearic acid succinic acid - concerta is indicated for the treatment of attention deficit hyperactivity disorder (adhd). a diagnosis of attention deficit hyperactivity disorder (adhd; dsm-iv) implies the presence of hyperactive-impulsive or inattentive symptoms that caused impairment and were present before age 7 years. need for comprehensive treatment programme: concerta is indicated as an integral part of a total treatment program for adhd that may include other measures (psychological, educational and social) for patients with this syndrome. stimulants are not intended for use in the patient who exhibits symptoms secondary to environmental factors and/or other primary psychiatric disorders, including psychosis. appropriate educational placement is essential and psychosocial intervention is often helpful. when remedial measures alone are insufficient, the decision to prescribe stimulant medication will depend upon the physician's assessment of the chronicity and severity of the patient's symptoms. long term use: the effectiveness of concerta for long-term use has not been systematically evaluated in controlled trials. therefore the physician who elects to use concerta for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient.

Concerta Extended Release Tablets Nowa Zelandia - angielski - Medsafe (Medicines Safety Authority)

concerta extended release tablets

janssen-cilag (new zealand) ltd - methylphenidate hydrochloride 54mg (drug layer 1, drug layer 2 & drug coat);   - modified release tablet - 54 mg - active: methylphenidate hydrochloride 54mg (drug layer 1, drug layer 2 & drug coat)   excipient: butylated hydroxytoluene carnauba wax cellulose acetate hypromellose ferric oxide, green (push layer) iron oxide red opacode black ns-78-17715 opadry clear ys-1-19025-a opadry red y-30-15567-a phosphoric acid poloxamer 188 polyethylene oxide povidone sodium chloride stearic acid succinic acid - concerta is indicated for the treatment of attention deficit hyperactivity disorder (adhd). a diagnosis of attention deficit hyperactivity disorder (adhd; dsm-iv) implies the presence of hyperactive-impulsive or inattentive symptoms that caused impairment and were present before age 7 years. need for comprehensive treatment programme: concerta is indicated as an integral part of a total treatment program for adhd that may include other measures (psychological, educational and social) for patients with this syndrome. stimulants are not intended for use in the patient who exhibits symptoms secondary to environmental factors and/or other primary psychiatric disorders, including psychosis. appropriate educational placement is essential and psychosocial intervention is often helpful. when remedial measures alone are insufficient, the decision to prescribe stimulant medication will depend upon the physician's assessment of the chronicity and severity of the patient's symptoms. long term use: the effectiveness of concerta for long-term use has not been systematically evaluated in controlled trials. therefore the physician who elects to use concerta for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient.

Dynastat Unia Europejska - angielski - EMA (European Medicines Agency)

dynastat

pfizer europe ma eeig - parecoxib sodium - pain, postoperative - coxibs, antiinflammatory and antirheumatic products - for the short-term treatment of postoperative pain in adults.,

Dyna- Doxycycline 100 mg Softgel Capsule Filipiny - angielski - FDA (Food And Drug Administration)

dyna- doxycycline 100 mg softgel capsule

crisdy-na drug corporation - doxycycline (as hyclate) - softgel capsule - 100 mg

DYNASTAT parecoxib (as sodium) 40mg powder for    injection vial Australia - angielski - Department of Health (Therapeutic Goods Administration)

dynastat parecoxib (as sodium) 40mg powder for injection vial

pfizer australia pty ltd - parecoxib sodium, quantity: 42.36 mg (equivalent: parecoxib, qty 40 mg) - injection, powder for - excipient ingredients: sodium hydroxide; phosphoric acid; dibasic sodium phosphate - for a single peri-operative dose for the management of post-operative pain.

DYNA-MAX 110- iodine solution Stany Zjednoczone - angielski - NLM (National Library of Medicine)

dyna-max 110- iodine solution

dairy dynamics l.l.c. - iodine (unii: 9679tc07x4) (iodine - unii:9679tc07x4) - iodine 10 g in 1 l - dyna-max 110 teat dip formulation commercial 10,000 ppm iodine (1% iodine) contains 10% glycerin usage: post dip, pre-dip weather conditions: adverse organism challenge: high housing conditions: fair/good

Dynastat Powder and Solvent for Solution for Injection 40mg Singapur - angielski - HSA (Health Sciences Authority)

dynastat powder and solvent for solution for injection 40mg

pfizer private limited - parecoxib sodium 42.36mg eqv parecoxib - injection, powder, lyophilized, for solution - 40mg - parecoxib sodium 42.36mg eqv parecoxib 40mg

Dynastat Powder for Solution for Injection 40mg Singapur - angielski - HSA (Health Sciences Authority)

dynastat powder for solution for injection 40mg

pfizer private limited - parecoxib sodium 42.36mg eqv parecoxib - injection, powder, lyophilized, for solution - 40mg - parecoxib sodium 42.36mg eqv parecoxib 40mg

Jurnista Prolonged Release Tablet 8mg Singapur - angielski - HSA (Health Sciences Authority)

jurnista prolonged release tablet 8mg

johnson & johnson pte. ltd. - (drug layer) hydromorphone hcl - tablet, extended release - 8.72mg - (drug layer) hydromorphone hcl 8.72mg